CliffBio
small molecule

ALCAFTADINE

ALCAFTADINE

Loss of exclusivity—loss of exclusivity
CompanyAlembic →See this company's full patent-cliff portfolio

Drug detail

Brand nameALCAFTADINE
Active ingredientALCAFTADINE
Strength0.25%
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalOctober 2024
Marketing statusOTC

More from Alembic

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.